HLN
Haleon Sp ADR (HLN)
NYSE
$10.38+$0.36 (+3.54%)
Price as of Oct 22, 2026 7:30 PM EDT
  • $44.1B
    Market Cap
  • 8.18%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 57
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Haleon Launches ‘Haleon Health House,’ a One-Day Interactive Wellness Pop-Up in Toronto

Haleon Canada is opening a limited-time immersive experience called the 'Haleon Health House' in Toronto on October 23, 2026, showcasing its portfolio of health brands including Advil, Buckley's, Centrum, and Sensodyne. The activation aims to address a confidence gap in everyday health decisions among Canadians, particularly Gen Z, by providing expert guidance and interactive product demonstrations.

10/19/2026, 7:00 AM • GlobeNewswire

Prediction: These 3 Dividend Stocks Will Raise Their Payouts No Matter What the Market Does

The article identifies three dividend stocks with strong fundamentals and resilient business models that are likely to continue raising payouts through economic downturns: WD-40 Company with 40 years of uninterrupted dividends backed by an iconic product with minimal competition, Energizer Holdings yielding 5.9% with essential consumer products, and Haleon with a conservative payout policy and health brands used by over a billion consumers worldwide.

10/14/2026, 2:30 AM • The Motley Fool

Dietary Supplements Market to Cross USD 187 Bn by 2031 as Gummies, Liquids, and Functional Formats Gain Traction, 2026 Mordor Intelligence Report

The global dietary supplements market is projected to grow from USD 151.82 billion in 2026 to USD 187.22 billion by 2031 at a CAGR of 4.28%. Growth is driven by preventive healthcare adoption, aging populations, and shifting consumer preferences toward convenient formats like gummies and liquids. Asia-Pacific leads market share, while clean-label and personalized nutrition solutions are reshaping the industry.

01/23/2026, 3:45 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$10.02
$10.15
$10.02
1-Year Range
$8.70
$11.27
$10.02
Latest Close$10.02
Change
-$0.15 (-1.50%)
Volume13,006,393
Market Cap$44.1B
Shares Outstanding4.4B
P/E (TTM)54.16
Diluted EPS (TTM)$0.19
Enterprise Value$42.7B

Information as of 10/21/2026

Company Profile

$44.1B
Market Cap
$1.7B
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
The Heights, Weybridge, United Kingdom, KT13 0NY
44 1932 959 500

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Key Executives

  • Brian James McNamara
  • Dawn Amanda Allen
  • Adrian Charles Morris
  • Bjorn Timelin
  • Filippo Lanzi

Current Ownership Distribution

  • Institutions5.9B (71.99%)
  • Mutual Funds2.3B (28.01%)
  • Insiders0 (0.00%)
  • Other0 (0.00%)